


What is claimed is:

1. A compound according to Formula I herein below:







**Formula (I)**

wherein:

R<sup>1</sup> is selected from the group consisting of a substituent selected from: C<sub>1</sub>-<sub>6</sub> alkanoyl, aroyl and aroylC<sub>1</sub>-<sub>6</sub>alkyl, all optionally substituted;

R<sup>2</sup> is selected from the group consisting of a hydrogen atom or a C<sub>1</sub>-<sub>4</sub>alkyl group;

G is selected from the group consisting of C<sub>4</sub>-<sub>7</sub>alkyl or a group of the formula (a), (b), (c) or (d)



(a)

(b)


(c)

(d)


Wherein,

R<sup>3</sup> and R<sup>4</sup> are, independently, selected from a group consisting of a hydrogen, C<sub>1</sub>-<sub>4</sub>alkyl, aryl, or C<sub>1</sub>-<sub>2</sub>alkylaryl;

A is selected from a group consisting of an optionally substituted C<sub>1</sub>-<sub>6</sub>alkyl or a group of the formula (e), (f), (g) or (h):




(e)



(f)



(g)



(h)

wherein

X is selected from a group consisting of a bond, NR<sup>2</sup>, O or S;

Ar is selected from a group consisting of an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring; or an optionally substituted bicyclic or heterobicyclic ring system;

Ar<sup>1</sup> and Ar<sup>2</sup> are, independently, selected from a group consisting of an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring; and

Y is selected from a group consisting of a bond, -NHCO-, -CONH-, -CH<sub>2</sub>-, or -(CH<sub>2</sub>)<sub>m</sub>Y<sup>1</sup>(CH<sub>2</sub>)<sub>n</sub>-, wherein Y<sup>1</sup> is selected from a group consisting of O, S, SO<sub>2</sub>, or CO and m and n each represent zero or 1 such that the sum of m+n is zero or 1; provided that when A represents a group of formula (a), any substituent present in Ar *ortho* to the carboxamide moiety is necessarily a hydrogen or a methoxy group;

r and s are, independently, selected from a group consisting of an integer from zero to 3 such that the sum of r and s is equal to an integer from 1 to 6;

V is selected from a group consisting of a bond, O, S, -NHCO-, -CONH-, CHNHCOR<sup>3</sup>; and salts thereof.

2. A compound according to claim 1 consisting of the group selected from:

2,8-dimethyl-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-5-quinolinecarboxamide;  
 2,8-Dimethyl-quinoline-5-carboxylic acid {4-[2-(7-butyryl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-amide;  
 8-Methoxy-2-methyl-quinoline-5-carboxylic acid {4-[2-(7-butyryl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-amide;  
 8-Chloro-2-methyl-quinoline-5-carboxylic acid {4-[2-(7-butyryl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-amide;  
 N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-5-quinolinecarboxamide;  
 N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-2,2-diphenylacetamide;  
 2-Methyl-quinoline-5-carboxylic acid {4-[2-(7-butyryl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-amide;  
 N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-1H-indole-2-carboxamide;

1,1-dimethylethyl 2-[[[(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)amino]carbonyl}benzoate;  
 8-chloro-2-methyl-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-5-quinolinecarboxamide;  
 2-methyl-8-(methyloxy)-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-5-quinolinecarboxamide;  
 8-chloro-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-5-quinolinecarboxamide;

3. A compound according to claim 1 consisting of the group selected from:

1,1-dimethylethyl ((1S)-2-[(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)amino]-2-oxo-1-[[[(phenylmethyl)oxy]methyl]ethyl]carbamate formate;  
 N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-N'-(phenylmethyl)butanediamide;  
 N-{5-[(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)amino]-5-oxopentyl}benzamide;  
 N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-2-[(methylsulfonyl)amino]benzamide;  
 N<sup>1</sup>-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-O-(phenylmethyl)-L-serinamide;  
 N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-1-isoquinolinecarboxamide formate;  
 N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-1,6-naphthyridine-2-carboxamide;  
 1,1-dimethylethyl ({3-[(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)amino]-3-oxopropyl}thio)acetate;  
 2-(dimethylamino)-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)benzamide;  
 N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-3,3-diphenylpropanamide;  
 N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-2-(2-naphthalenyl)acetamide formate;

(2E)-3-(1H-imidazol-4-yl)-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-2-propenamide;  
N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-6-(1H-pyrrol-1-yl)-3-pyridinecarboxamide;  
4-amino-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)butanamide;  
N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-4-pyridinecarboxamide formate;  
1,1-dimethylethyl {4-[(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)amino]-4-oxobutyl}carbamate;  
3-[3,4-bis(methyloxy)phenyl]-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)propanamide;  
N-{2-[(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)amino]-2-oxoethyl}-3-pyridinecarboxamide formate ;  
N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-1-phenylcyclopentanecarboxamide;  
2-[4-(dimethylamino)phenyl]-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)acetamide;  
N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-1,8-naphthyridine-2-carboxamide;  
N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-2-(4-pyridinyl)acetamide;  
N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-4-oxo-4-phenyl-2-butenamide;  
2-(5-hydroxy-1H-benzimidazol-1-yl)-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)acetamide;  
N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-2-pyrazinecarboxamide;  
1-methyl-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-1H-indole-2-carboxamide;  
N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-2-(3-pyridinyl)-1,3-thiazole-4-carboxamide;  
1,1-dimethylethyl {(1R)-2-[(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)amino]-2-oxo-1-phenylethyl}carbamate;

N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-3-pyridinecarboxamide 1-oxide formate;  
3-(dimethylamino)-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)benzamide;  
N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-1H-indole-2-carboxamide;  
3-(1H-indol-3-yl)-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)propanamide;  
N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-2-quinolinecarboxamide;  
N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-2-(1H-pyrrol-1-yl)benzamide;  
1,1-dimethylethyl [(1R)-2-[(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)amino]-2-oxo-1-(3-pyridinylmethyl)ethyl]carbamate formate;  
N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-1H-indole-3-carboxamide formate;  
5-methyl-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-2-phenyl-2H-1,2,3-triazole-4-carboxamide;  
N<sup>3</sup>-[(4-methylphenyl)sulfonyl]-N<sup>1</sup>-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-beta-alaninamide formate;  
(2R)-2-amino-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-2-phenylethanamide;  
N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-2-(2-pyrimidinylthio)acetamide formate;  
N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-4-(1H-pyrrol-1-yl)benzamide;  
N<sup>1</sup>-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-3-(3-pyridinyl)-D-alaninamide;  
(3E)-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-4-phenyl-3-butenamide;  
2-(1H-indol-3-yl)-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)acetamide;  
N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)-2-[(phenylmethyl)thio]acetamide;

4-[4-(methyloxy)phenyl]-N-(trans-4-{2-[7-(2-methylpropanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]ethyl}cyclohexyl)butanamide;

2-Methyl-quinoline-5-carboxylic acid {4-[7-(2-methyl-propanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-butyl}-amide;

2-Methyl-quinoline-5-carboxylic acid {8-[7-(2-methyl-propanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-octyl}-amide;

2-Methyl-quinoline-5-carboxylic acid [{4-[7-(2-methyl-propanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-ylmethyl]-cyclohexylmethyl}-carbamoyl]-methyl}-amide;

(R)-1-[1-(2-Methyl-quinolin-5-yl)-methanoyl]-pyrrolidine-2-carboxylic acid {4-[7-(2-methyl-propanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-ylmethyl]-cyclohexylmethyl}-amide

2-Methyl-quinoline-5-carboxylic acid;

[2-({4-[7-(2-methyl-propanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-ylmethyl]-cyclohexylmethyl}-carbamoyl)-ethyl]-amide;

2,8-Dimethyl-quinoline-5-carboxylic acid {4-[2-(7-butyryl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-amide;

8-Methoxy-2-methyl-quinoline-5-carboxylic acid {4-[2-(7-butyryl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-amide;

8-Chloro-2-methyl-quinoline-5-carboxylic acid {4-[2-(7-butyryl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-amide;

2-Methyl-quinoline-5-carboxylic acid {4-[2-(7-butyryl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-amide;

N-{4-[2-(7-Acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-4-fluoro-benzamide;

N-{4-[2-(7-Acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-3-(5-methyl-[1,2,4] oxadiazol-3-yl)-benzamide;

2-Methyl-quinoline-5-carboxylic acid {4-[2-(7-(2-methyl-propanoyl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-amide;

1H-pyrrolo[2,3-*b*]pyridine-3-carboxylic acid -{4-[2-(7-Acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-amide;

(E)-N-{4-[2-(7-Acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-3-(4-fluorophenyl)-acrylamide;

(E)-N-{4-[2-(7-Acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-3-(3-methoxyphenyl)-acrylamide;

(E)-N-{4-[2-(7-Acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-3-(2-cyanophenyl)-acrylamide;

(*E*)-*N*-{4-[2-(7-Acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-3-(2-acetylphenyl)-acrylamide;  
(*E*)-*N*-{4-[2-(7-Acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-3-(3-thiophenyl)-acrylamide;  
(*E*)-*N*-{4-[2-(7-Acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-3-(8-(1,2-dihydro-2-oxo)-quinolinyl)-acrylamide;  
(*E*)-*N*-{4-[2-(7-Acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-3-(3-benzothiophenyl)-acrylamide;  
(*E*)-*N*-{4-[2-(7-Acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-3-(3-benzothiophenyl)-acrylamide;  
(*E*)-3-(4-Acetylamino-phenyl)-*N*-{4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-acrylamide;  
*N*-{4-[2-(7-Acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-2-(2-aminobenzothiazol-6-yl)-acetamide;  
4-Oxo-1,4-dihydro-quinoline-8-carboxylic acid-{4-[2-(7-Acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-amide;  
*N*-{4-[2-(7-Acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-ethyl]-cyclohexyl}-2-(benzo[*b*]thiophen-2-yl)-acetamide  
and pharmaceutically acceptable salts thereof.

4. A pharmaceutical composition for the treatment of muscarinic acetylcholine receptor mediated diseases comprising a compound according to claim 1 and a pharmaceutically acceptable carrier thereof.
5. A method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof comprising administering a safe and effective amount of a compound according to claim 1.
6. A method of treating a muscarinic acetylcholine receptor mediated disease, wherein acetylcholine binds to said receptor, comprising administering a safe and effective amount of a compound according to claim 1.
7. A method according to claim 6 wherein the disease is selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.

8. A method according to claim 7 wherein administration is via inhalation via the mouth or nose.
9. A method according to claim 8 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler.
10. A method according to claim 9 wherein the compound is administered to a human and has a duration of action of 12 hours or more for a 1 mg dose.
11. A method according to claim 10 wherein the compound has a duration of action of 24 hours or more.
12. A method according to claim 11 wherein the compound has a duration of action of 36 hours or more.